Elliott Levy Sells Shares of NCNA
Elliott Levy recently sold shares of NCNA, with the stock trading at $1.73.
Key Points
- Elliott Levy sold shares of NCNA on June 19, 2026, with shares trading at $1.73 on Wednesday.
- NCNA has seen recent activity from peers like Citadel Advisors and Jane Street Group adjusting their positions.
- Oppenheimer maintained a buy rating on NCNA with a $150 price target as of July 22, 2024.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Elliott Levy sold shares of NCNA on June 19, 2026. The stock was trading at $1.73 on Wednesday. This insider transaction wasn't part of a pre-planned trading program.
Other Institutional Activity in NCNA
Several institutional investors have recently adjusted their holdings in NCNA. Citadel Advisors LLC opened a new position, acquiring 13,855 shares valued at about $19,536. Similarly, Virtu Financial LLC also initiated a stake with 13,433 shares worth approximately $19,000. Meanwhile, Jane Street Group, LLC reduced its holdings by 819 shares, bringing its total to 10,511 shares valued at around $14,715, marking a 7.2% decrease. Rhumbline Advisers also trimmed its position by 1,187 shares, ending with 3,722 shares worth about $5,245, a 24.2% decrease.
NuCana plc Stock Down 1.7%
Shares of NCNA traded near $1.73 on Wednesday. The stock has seen varied activity from institutional investors, reflecting a dynamic market environment. As of now, detailed financial metrics like market cap and P/E ratio are not available.
$NCNA stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at NuCana plc
On June 19, 2026, Elliott Levy sold shares of NCNA. On the same day, Jeffrey Bloss, Chief Medical Officer, also sold shares. Earlier, on April 15, 2026, Theresa Margaret Bruce, the Chief Operating Officer, bought shares, indicating diverse trading activities among company insiders.
Analysts Set New Price Targets
On July 22, 2024, Oppenheimer maintained a buy rating on NCNA, setting a price target of $150. This reflects the firm's positive outlook on the stock.
Bottom Line
Insider transactions like those by Elliott Levy provide insight into company dynamics, though they don't necessarily signal market direction. Institutional investors have shown varied interest in NCNA, with some opening new positions while others reduce their holdings. Analyst opinions, such as Oppenheimer's maintained buy rating, offer additional perspectives on the stock's potential. Remember, 13F filings and insider trades are backward-looking and may not reflect current positions.
Get NuCana plc alerts
New 13F filings, insider trades, and analyst moves on $NCNA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.